PRMT5 inhibitors: Therapeutic potential in pancreatic cancer

PRMT5 inhibitors: Therapeutic potential in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is predominantly driven by mutations in the Kirsten rat sarcoma virus (KRAS) oncogene. Due to the pivotal role of KRAS in PDAC pathogenesis, KRAS inhibitors (KRASi) have recently demonstrated initial signs of clinical efficacy. However, considering currently d...

Full description

Saved in:
Bibliographic Details
Main Authors: Carolin Schneider, Valentina Spielmann, Christian J. Braun, Günter Schneider
Format: Article
Language:English
Published: Elsevier 2025-05-01
Series:Translational Oncology
Subjects:
Pancreatic cancer
KRAS
PRMT5
Resistance
Immunotherapies
Online Access:http://www.sciencedirect.com/science/article/pii/S193652332500097X
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items